Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

Brian W Labadie,1 David S Morris,2 Alan H Bryce,3 Robert Given,4,5 Jingsong Zhang,6 Wassim Abida,7 Simon Chowdhury,8,9 Akash Patnaik1 1Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA; 2Urology Associates, P.C., Nashville, TN, USA; 3Hematology and Medic...

Full description

Bibliographic Details
Main Authors: Labadie BW, Morris DS, Bryce AH, Given R, Zhang J, Abida W, Chowdhury S, Patnaik A
Format: Article
Language:English
Published: Dove Medical Press 2022-02-01
Series:Cancer Management and Research
Subjects:
poly(adp-ribose) polymerase inhibitors
rucaparib
metastatic castration-resistant prostate cancer
adverse drug reaction
Online Access:https://www.dovepress.com/guidelines-for-management-of-treatment-emergent-adverse-events-during--peer-reviewed-fulltext-article-CMAR

Internet

https://www.dovepress.com/guidelines-for-management-of-treatment-emergent-adverse-events-during--peer-reviewed-fulltext-article-CMAR

Similar Items